Aurobindo Pharma Faces ₹4.60 Crore Tax Demand via Appellate Order
Aurobindo Pharma Ltd · Others (Uncategorized) · 29 Sept 2026, 10:15 pm
Aurobindo Pharma Faces ₹4.60 Crore Tax Demand via Appellate Order Aurobindo Pharma received an order dated 28th Sep'26 from the Appellate Joint Commissioner (ST), Hyderabad, confirming a total disputed demand of ₹4.60 crore for FY21. This comprises a tax reversal of ₹2.56 crore for alleged excess Input Tax Credit claims, ₹1.78 crore in interest, and a ₹0.26 crore penalty. The company plans to appeal the order before the GST Appellate Tribunal and stated the ruling has no material impact on its financials or operations.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. · 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. · 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". · 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. · 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. · 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. · 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. · 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. · 05 Nov 2026
